

## AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all previous listings and versions of claim in this application.

1. (Currently Amended) An isolated polynucleotide comprising a transcript of a T cell receptor (TCR) gene, said ~~polynucleotide transcript~~ lacking V region sequences and comprising:
  - a constant (C) domain;
  - ~~and a joining (J) region sequences~~ sequence; and
  - a 5' intronic J ~~sequences~~ sequence that is upstream to said J region sequence, ~~including~~ wherein said 5' intronic J sequence includes an in-frame methionine codon.
2. (Original) The polynucleotide according to claim 1, wherein the gene is a TCR $\beta$  gene.
3. (Original) The polynucleotide according to claim 2, wherein the joining (J) gene sequence is selected from J $\beta$ 2.1 and J $\beta$ 2.6.
4. (Original) The polynucleotide according to claim 3, wherein the joining (J) gene sequence is J $\beta$ 2.1 and said 5' intronic J sequence including an in-frame methionine codon codes for a peptide of the sequence M E N V S N P G S C I E E G E E R G R I L G S P F L [SEQ ID NO:1].
5. (Original) The polynucleotide according to claim 3, wherein the joining (J) gene sequence is J $\beta$ 2.6 and said 5' intronic J sequence including a methionine codon codes for a peptide of the sequence M G E Y L A E P R G F V C G V E P L C [SEQ ID NO: 2].
6. (Original) The polynucleotide according to claim 1, comprising a 5' intronic J sequence encoding a peptide selected from any one of SEQ ID NOs:1-37.

7. (Original) The polynucleotide of claim 2, wherein the joining J gene sequence is the intronic J $\beta$ 2.3 gene sequence coding for the peptide:

M G L S A V G R T R A E S G T A E R A A P V F V L G L Q A V [SEQ ID NO: 17].

8. (Original) The polynucleotide according to claim 1, wherein the gene is a TCR $\alpha$  gene.

9. (Original) The cDNA molecule according to claim 8, wherein the joining (J) gene sequence is selected from human or murine J $\alpha$  genes.

10. (Previously Presented) The cDNA molecule according to claim 9, wherein said 5' intronic J sequence including an in-frame methionine codon is selected from the group consisting of:

(i) the intronic J $\alpha$ TA31 gene sequence coding for the peptide:

M A W H [SEQ ID NO:3].

(ii) the intronic J $\alpha$ TA46 gene sequence coding for the peptide:

M E A G W E V Q H W V S D M E C L T V [SEQ ID NO:4].

(iii) the intronic J $\alpha$ TA46 gene sequence coding for the peptide:

M E C L T V [SEQ ID NO:5].

(iv) the intronic J $\alpha$ New05 gene sequence coding for the peptide:

M T V [SEQ ID NO:6].

(v) the intronic J $\alpha$ S58 gene sequence coding for the peptide:

M C G S E E V F V V E S A [SEQ ID NO:7].

(vi) the intronic J $\alpha$ New06 gene sequence coding for the peptide:

M A C Y Q M Y F T G R K V D E P S E L G S G L

E L S Y F H T G G S S Q A V G L F I E N M I S T S

H G H F Q E M Q F S I W S F T V L Q I S A P G S H

L V P E T E R A E G P G V F V E H D I [SEQ ID NO:8].

(vii) the intronic J $\alpha$ New06 gene sequence coding for the peptide:

M Y F T G R K V D E P S E L G S G L E L S Y F H T G G

SSQAVGLFIENMISTS

HGHFQEMQFSIWSFTVLQISAPGSH

LVPETERAEGPGVFVEHDI [SEQ ID NO:9].

- (viii) the intronic J $\alpha$ New06 gene sequence coding for the peptide:

MISTSHGHFQEMQFSIWSFTVLQISAPGSH

LVPETERAEGPGVFVEHDI [SEQ ID NO:10].

- (ix) the intronic J $\alpha$ New06 gene sequence coding for the peptide:

MQFSIWSFTVLQISAPGSH

LVPETERAEGPGVFVEHDI [SEQ ID NO:11].

- (x) the intronic J $\alpha$ New08 gene sequence coding for the peptide:

MWWGLILSASVKFLQRKEILC [SEQ ID NO:12].

- (xi) the intronic J $\alpha$ LB2A gene sequence coding for the peptide:

MVGADLCKGGWHCV [SEQ ID NO:13].

- (xii) the intronic J $\alpha$ DK1 gene sequence coding for the peptide:

MREPVKNLQGLVS [SEQ ID NO:14].

- (xiii) the intronic J $\alpha$ TA39 gene sequence coding for the peptide:

MEVYELRVTLMETGRERSHFVKTSL [SEQ ID NO:15]; and

- (xiv) the intronic J $\alpha$ TA39 gene sequence coding for the peptide:

METGRERSHFVKTSL [SEQ ID NO:16].

11. (Previously Presented) The polynucleotide according to claim 8, wherein said 5' intronic J sequence including an in-frame methionine codon is selected from the group consisting of:

- (i) the intronic J $\alpha$ 3 gene sequence coding for the peptide:

MLLWDPSGFQQISIKKVISKTLPT [SEQ ID NO:18].

- (ii) the intronic J $\alpha$ 6 gene sequence coding for the peptide:

MLPNTMGQLVEGGHMKQVLSKAVLTV [SEQ ID NO:19].

- (iii) the intronic J $\alpha$ 6 gene sequence coding for the peptide:

MGQLVEGGHMKQVLSKAVLTV [SEQ ID NO:20].

- (iv) the intronic J $\alpha$ 6 gene sequence coding for the peptide:

M K Q V L S K A V L T V [SEQ ID NO:21].

(v) the intronic J $\alpha$ 8 gene sequence coding for the peptide:

M S E C [SEQ ID NO:22].

(vi) the intronic J $\alpha$ 9 gene sequence coding for the peptide:

M A H F V A V Q I T V [SEQ ID NO:23].

(vii) the intronic J $\alpha$ 11 gene sequence coding for the peptide:

M G I C Y S [SEQ ID NO:24].

(viii) the intronic J $\alpha$ 13 gene sequence coding for the peptide:

M K R A G E G K S F C K G R H Y S V [SEQ ID NO:25].

(ix) the intronic J $\alpha$ 14 gene sequence coding for the peptide:

M L T T L I Y Y Q G N S V I F V R Q H S A [SEQ ID NO:26].

(x) the intronic J $\alpha$ 24 gene sequence coding for the peptide:

M Q L P H F V A R L F P H E Q F V F I Q Q L S S L G K P F C R G V C H S V [SEQ ID NO:27].

(xi) the intronic J $\alpha$ 31 gene sequence coding for the peptide:

M G F S K G R K C C G [SEQ ID NO:28].

(xii) the intronic J $\alpha$ 36 gene sequence coding for the peptide:

M K K I W L S R K V F L Y W A E T L [SEQ ID NO:29].

(xiii) the intronic J $\alpha$ 40 gene sequence coding for the peptide:

M G K V H V M P L L F M E S K A A S I N G N I M L V Y V E T H N T V [SEQ ID NO:30].

(xiv) the intronic J $\alpha$ 40 gene sequence coding for the peptide:

M P L L F M E S K A A S I N G N I M L V Y V E T H N T V [SEQ ID NO:31].

(xv) the intronic J $\alpha$ 40 gene sequence coding for the peptide:

M E S K A A S I N G N I M L V Y V E T H N T V [SEQ ID NO:32].

(xvi) the intronic J $\alpha$ 40 gene sequence coding for the peptide:

M L V Y V E T H N T V [SEQ ID NO:33].

(xvii) the intronic J $\alpha$ 41 gene sequence coding for the peptide:

M E E G S F I Y T I K G P W M T H S L C D C C V I G F Q T L A L I G I I G E G T W  
W L L Q G V F C L G R T H C [SEQ ID NO:34].

(xviii) the intronic J $\alpha$ 41 gene sequence coding for the peptide:

M T H S L C D C C V I G F Q T L A L I G I I G E G T W W L L Q G V F C L G R T H  
C [SEQ ID NO:35].

(xix) the intronic J $\alpha$ 44 gene sequence coding for the peptide:

M E S Q A T G F C Y E A S H S V [SEQ ID NO:36].

12. (Withdrawn) An antisense polynucleotide of the polynucleotides according to claim 1.

13. (Currently Amended) An expression vector comprising ~~a~~ the polynucleotide according to claim 1.

14. (Currently Amended) A host cell comprising ~~a~~ the expression vector according to claim 13, wherein the host is a mammalian cell.

15. (Currently Amended) ~~Transfected mesenchymal~~ Mesenchymal human cells transfected with the expression vector according to claim ~~14~~ 13.

16. (Currently Amended) A polypeptide encoded by ~~a~~ the polynucleotide according to claim 1.

17. (Currently Amended) ~~A~~ An isolated polynucleotide comprising SEQ ID NO:38.

18. (Withdrawn) A synthetic peptide deduced from an intronic J sequence of a TCR.

19. (Withdrawn) The synthetic peptide according to claim 18 selected from the group consisting of any one of SEQ ID Nos: 1-16 or SEQ ID Nos: 17-36.

20. (Withdrawn) An antibody raised against a peptide according to claim 18.

21. (Withdrawn) An antibody raised against a peptide according to claim 19.

22. (Withdrawn) A method for inducing mesenchymal cell growth comprising administering to a subject in need thereof transfected mesenchymal human cells comprising a polynucleotide according to claim 1, in an amount effective to induce mesenchymal cell growth.

23. (Withdrawn) The method according to claim 22, wherein the method induces wound healing.

24. (Withdrawn) A method for suppressing mesenchymal cell growth comprising administering to a subject in need thereof transfected mesenchymal human cells comprising a DNA molecule according to claim 12, in an amount effective to suppress mesenchymal cell growth.

25. (Withdrawn) The method according to claim 24, wherein the method suppresses carcinomas.

26. (Withdrawn) A method of marking mesenchymal cells comprising applying an antibody according to claim 20 to mesenchymal cells in an amount effective to mark the cells.

27. (New) The polynucleotide according to claim 1, wherein the transcript is expressed in stromal mesenchymal cells.